Organon & Co. (NYSE:OGN) Shares Sold by Lewis Asset Management LLC

Lewis Asset Management LLC decreased its stake in Organon & Co. (NYSE:OGN) by 9.0% during the 4th quarter, HoldingsChannel reports. The firm owned 10,131 shares of the company’s stock after selling 1,005 shares during the period. Lewis Asset Management LLC’s holdings in Organon & Co. were worth $151,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Prospera Private Wealth LLC acquired a new position in shares of Organon & Co. during the third quarter valued at $25,000. Horizon Bancorp Inc. IN lifted its position in Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares during the last quarter. Abich Financial Wealth Management LLC boosted its stake in Organon & Co. by 5,646.3% during the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after purchasing an additional 2,315 shares during the period. Trust Co. of Vermont boosted its stake in Organon & Co. by 109.4% during the 3rd quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after purchasing an additional 1,372 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its position in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of OGN opened at $15.85 on Thursday. The firm has a market capitalization of $4.08 billion, a PE ratio of 3.14, a P/E/G ratio of 0.87 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a 50-day moving average price of $15.44 and a 200 day moving average price of $17.98. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the business earned $0.78 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. On average, sell-side analysts anticipate that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $21.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.